ÐÂÎÅ×ÊѶ
ÈÈÁÒ×£ºØ | ½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚÖÆÒ©¼¯ÍÅʯɼ¼î¼×»ñµÃÃÀ¹úFDA¡°ÓÐÊý¶ù¿Æ¼²²¡¡±Ò©ÎïÈ϶¨£¡
ÈÕÆÚ£º
2024Äê05ÔÂ17ÈÕ 15:53
½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú£¨ÒÔϼò³Æ“½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚÖÆÒ©”£©ÓÚ2024Äê5ÔÂ1ÈÕÊÕµ½ÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨ÒÔϼò³Æ“FDA”£©µÄÈ϶¨º¯£¬£¬ £¬£¬£¬ £¬£¬£¬¹«Ë¾²úƷʯɼ¼î¼×ÓÃÓÚÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¡£¡£¡£¡£¨HIE£©»ñµÃFDAÊÚÓèµÄ“ÓÐÊý¶ù¿Æ¼²²¡”£¨Rare Pediatric Disease,RPD£©Ò©ÎïÈ϶¨¡£¡£¡£¡£¡£
×ʸñÈ϶¨ÇéÐÎ
¹«Ë¾ÓÚ2024Äê3ÔÂÏòFDAÌá½»¹ØÓÚʯɼ¼î¼×RPDÒ©ÎïÈ϶¨µÄÏà¹ØÉêÇ룬£¬ £¬£¬£¬ £¬£¬£¬ÉêÇëºÅRPD-2024-812£¬£¬ £¬£¬£¬ £¬£¬£¬»ñµÃFDA»Øº¯È·ÈÏ:“ÎÒÃÇÌØ´ËÅú×¼¹ó˾µÄÇëÇ󣬣¬ £¬£¬£¬ £¬£¬£¬½«ÓÃÓÚÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡£¡£¡£¡£¡£¨HIE£©µÄʯɼ¼î¼×Ö¸¶¨Îª¡¶Áª°îʳÎï¡¢Ò©Æ·ºÍ»¯×±Æ··¨°¸¡·£¨FD&C·¨°¸£©µÚ529Ìõ(a)(3)£¨21 U.S.C.360ff(a)(4)£©Ëù½ç˵µÄ“ÓÐÊý¶ù¿Æ¼²²¡”Ò©Îï¡£¡£¡£¡£¡£”
Ò©Îï»ù±¾ÇéÐÎ
ÐÂÉú¶ù HIE ÊÇÓÉÄÔ×é֯ȱÑõºÍÄÔѪÁ÷Á¿ïÔÌÒýÆðµÄÒ»ÖÖÐÂÉú¶ùÄÔËðÉ˼²²¡£¬£¬ £¬£¬£¬ £¬£¬£¬ÏÖÔÚÖÎÁÆ·½·¨°üÀ¨Ö§³ÖÁÆ·¨¡¢¿ØÖƾªØÊ¡¢ÖÎÁÆÄÔË®Öס¢ÑǵÍÎÂÖÎÁƵȡ£¡£¡£¡£¡£
ʯɼ¼î¼×Ö÷Òª×÷ÓûúÀíΪÒÒõ£µ¨¼îõ¥Ã¸ÒÖÖÆ£¬£¬ £¬£¬£¬ £¬£¬£¬Í¬Ê±¾ßÓп¹Ñס¢¿¹Ñõ»¯Ó¦¼¤ÓëÉñ¾± £»£»£»£»£»£»£»¤µÈ×÷Ó㬣¬ £¬£¬£¬ £¬£¬£¬ÊÊÓÃÓÚÁ¼ÐÔÓ°ÏóÕÏ°£¬£¬ £¬£¬£¬ £¬£¬£¬Ìá¸ß»¼ÕßÖ¸ÏòÓ°Ïó¡¢åÚÏëѧϰ¡¢Í¼Ïñ»ØÒä¡¢ÎÞÒâÒåͼÐÎÔÙÈϼ°ÈËÏñ»ØÒäµÈÄÜÁ¦£¬£¬ £¬£¬£¬ £¬£¬£¬¶Ô³Õ´ô»¼ÕߺÍÄÔÆ÷ÖÊÐÔ²¡±äÒýÆðµÄÓ°ÏóÕÏ°ÒàÓиÄÉÆ×÷Ó㬣¬ £¬£¬£¬ £¬£¬£¬ÒàÓÃÓÚÖØÖ¢¼¡ÎÞÁ¦µÄÖÎÁÆ¡£¡£¡£¡£¡£
»ñµÃÃÀ¹úFDA“ÓÐÊý¶ù¿Æ¼²²¡”Ò©Îï×ʸñÈ϶¨µÄÓ°Ïì
ÏÖÔÚ¹«Ë¾Ê¯É¼¼î¼×ÖÊÁÏÒ©Óëʯɼ¼î¼××¢ÉäÒºÒÑÉÏÊÐÏúÊÛ£¬£¬ £¬£¬£¬ £¬£¬£¬Ê¯É¼¼î¼×¿ØÊÍƬÒѽøÈëÁÙ´²ÊÔÑé½×¶Î¡£¡£¡£¡£¡£±¾´Îʯɼ¼î¼×ÖÎÁÆÐÂÉú¶ùȱÑõȱѪÐÔÄÔ²¡Ë³Ó¦Ö¢»ñµÃ FDA“ÓÐÊý¶ù¿Æ¼²²¡”Ò©Îï×ʸñÈ϶¨£¬£¬ £¬£¬£¬ £¬£¬£¬¼ÓËÙÁ˹«Ë¾Ò©Æ·¹ú¼Ê»¯Õ½ÂԽṹ¡£¡£¡£¡£¡£FDA ΪÃãÀøÓÐÊý¡¢ÑÏÖغÍΣ¼°ÉúÃüµÄ¶ù¿ÆÒ©ÎïµÄ¿ª·¢¶øÉèÁ¢µÄ“ÓÐÊý¶ù¿Æ¼²²¡”Ò©Îï×ʸñÈ϶¨£¬£¬ £¬£¬£¬ £¬£¬£¬ÎªÓÐÊý¡¢ÑÏÖصĶù¿ÆÐÂÒ©¿ª·¢Ìṩ¼¤Àø£¬£¬ £¬£¬£¬ £¬£¬£¬¹«Ë¾½«Óлú»áÔÚ²úÆ·Ñз¢¡¢×¢²áµÈ·½ÃæÏíÊÜÃÀ¹úµÄÕþ²ßÖ§³Ö£¬£¬ £¬£¬£¬ £¬£¬£¬°üÀ¨ FDA ¹ØÓÚÁÙ´²¿ª·¢µÄÖ¸µ¼¡£¡£¡£¡£¡£ÈôδÀ´Ê¯É¼¼î¼×ÖÎÁÆÐÂÉú¶ùHIEµÄÐÂÒ©ÉêÇë»ñµÃÅú×¼£¬£¬ £¬£¬£¬ £¬£¬£¬ÔòÓлú»áÉêÇë»ñµÃFDAÊÚÓèµÄÓÅÏÈÉóÆÀȯ£¨PriorityReview Voucher,PRV£©¡£¡£¡£¡£¡£ÓÅÏÈÉóÆÀȯ¿ÉÓÃÓÚ¼ÓËÙÆóÒµÆäËû²úÆ·µÄÐÂÒ©ÉêÇëÉóÆÀÀú³Ì£¬£¬ £¬£¬£¬ £¬£¬£¬Òà¿É³öÊÛתÈøøÆäËûÐÂÒ©ÉÏÊÐÉêÇëÈË£¬£¬ £¬£¬£¬ £¬£¬£¬¸¶ÓëÊÜÈ÷½²úÆ· FDA ÓÅÏÈÉóÆÀȨÒæ¡£¡£¡£¡£¡£
Ïà¹ØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ